ROARABLE
FREE $100K
My Trading Account →
▾
Trading Account Active
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / OM / news
HYPR (38) ECOR (29) STXS (22) NRXS (36) ⌘ Pro Terminal →

Why OM Stock slipped -0.25% Today — RQD Quant Desk Flash

$4.02 -0.25% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.01

Outset Medical Inc. (OM) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $75.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Outset Medical Inc. (NASDAQ: OM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $4.02 (-0.25% 1D, market cap $75.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, OM ranks #638 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OM compare to HYPR and ECOR in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), OM carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 39.1%, and ROIC of -28.0%. By comparison, HYPR (Hyperfine Inc. (Class A)) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $76.1M) and ECOR (electroCore Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $67.8M). Among the 5-stock peer group, OM leads on earnings multiple (N/A) while OM leads on capital efficiency (-28.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OM?
▼

Per OM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001484612), Outset Medical Inc. generated $119.5M in revenue (+5.1% YoY), -$81.7M in net income, and -$47.1M in free cash flow against $264.5M in total assets and $96.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.01 (-0.23%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (8)Whales (7)SEC (8)Macro (6)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.7% Base Target
$14 Bull$4 Base$3 Bear
📬 FREE OM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OM)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY OM SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 39.1% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
42
Grade D$4.06+3.9% Next Q
Q2 (-2Q)
39
Grade E$4.22+2.8% Next Q
Q3 (-1Q)
37
Grade E$4.34-7.4% Next Q
Current
34
Grade E$4.02-8.7% Hist 90D α
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a OM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While OM currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.72) and Max Pain ($4.22) forces dealer call-delta covering toward $13.94.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why OM Stock slipped -0.25% Today — RQD Quant Desk Flash

Outset Medical Inc. (OM) slipped -0.25% to $4.02, trading at 11% of its 52-week range ($2.84 – $13.28). Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 11% of its 52-week range ($2.84 – $13.28) with RSI-14 at 51.2 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $4.02 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 39.1% gross margin and $0 annual free cash flow.
Live OM Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OM)

  • ✓Walkthrough of OM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
OM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -7.16%▼ DESCENDING CHANNEL
2026-11-03O $4.19H $4.19L $4.02C $4.02VOL 81.5K
RES: $4.41SUP: $2.23SMA50: $3.72SMA200: $4.14
$8.68$7.10$5.52$3.93$2.35RES $4.41SUP $2.23$4.022026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OM Butterfly Map → + Track OM →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +5.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on OM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OM)

Health Care Rank #638 of 1015 ⚔️ HYPR vs OM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OM vs. HYPR, ECOR, STXS, NRXS)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Outset Medical Inc. (OM) ranks #638 by composite RQD confidence (34/100, grade E) and #687 by equity capitalization ($75.8M). Within this direct 5-issuer industry benchmark cohort, OM leads on earnings valuation at N/A trailing P/E, while OM leads on capital efficiency and profitability with -28.0% ROIC and 39.1% gross margin. HYPR currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with OM at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
OM ACTIVE
Outset Medical Inc.
E 34/100 — 39.1% -28.0% -0.25% $75.8M Benchmark Subject
HYPR
Hyperfine Inc. (Class A)
D- 38/100 — 49.8% -35.0% +0.99% $76.1M /hypr-vs-om →
ECOR
electroCore Inc.
E 29/100 — 86.8% -35.0% -4.79% $67.8M /ecor-vs-om →
STXS
Stereotaxis Inc.
E 22/100 — 52.7% -35.0% +2.03% $86.4M /stxs-vs-om →
NRXS
Neuraxis Inc.
D- 36/100 — 84.2% -35.0% -7.43% $89.5M /nrxs-vs-om →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001484612 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Outset Medical Inc. (OM) reported GAAP revenue of $119.5M (+5.1% vs. FY2024 revenue of $113.7M , and -8.4% cumulative change since FY2023) , GAAP net income of -$81.7M, operating cash flow of -$46.3M, and free cash flow of -$47.1M (+59.8% YoY). On the balance sheet, OM closed FY2025 with $264.5M in total assets against $96.2M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $119.5M -$81.7M -$46.3M -$47.1M $264.5M $96.2M
FY2024 (FY) 2024-12-31 $113.7M -$128.0M -$116.3M -$117.2M $275.8M $197.4M
FY2023 (FY) 2023-12-31 $130.4M -$172.8M -$131.4M -$131.4M — —

3. OM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Outset Medical Inc. (NASDAQ: OM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $4.02 (-0.25% 1D, market cap $75.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, OM ranks #638 in composite RQD confidence.

How does OM compare to HYPR and ECOR in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), OM carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 39.1%, and ROIC of -28.0%. By comparison, HYPR (Hyperfine Inc. (Class A)) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $76.1M) and ECOR (electroCore Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $67.8M). Among the 5-stock peer group, OM leads on earnings multiple (N/A) while OM leads on capital efficiency (-28.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OM?

Per OM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001484612), Outset Medical Inc. generated $119.5M in revenue (+5.1% YoY), -$81.7M in net income, and -$47.1M in free cash flow against $264.5M in total assets and $96.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OM trading relative to its 50-day, 200-day, and 52-week technical levels?

OM last traded at $4.02 (-0.25% on volume of 54,276 shares), positioning the stock +8.06% above its 50-day simple moving average ($3.72) and -2.90% below its 200-day simple moving average ($4.14). Across its 52-week range of $2.84 to $13.28, OM sits at the 11.3% percentile with a 14-day RSI of 51.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.52 to $4.52).

Direct Sub-Reports: OM RQD Cockpit OM 12M Forecast OM Earnings & Move OM Dividends & DRIP OM Insiders & 13F OM Whale Options OM Profit Sankey OM News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

OM — Outset Medical Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Outset Medical Inc. (OM) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.02 (-0.25% 1D, market capitalization $75.8M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -28.0%, gross margin of 39.1%, operating margin of -55.8%, and free cash flow yield of —.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 6/9, and Debt/Equity of 0.76x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Outset Medical Inc. (OM) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry..1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Outset Medical Inc. (OM) reported $119.5M in annual revenue (up from $113.7M in FY2024, +5.1% YoY) and -$81.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($130.4M revenue, -$172.8M net income) through FY2025, OM scaled operating cash flow to -$46.3M and free cash flow to -$47.1M, backed by $264.5M in total assets against $96.2M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 7/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $2.84 – $13.28 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -55.8% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), OM carries a macro regime beta of 1.00 and gross margin of 39.1%.

  • Key Question #1: Can OM sustain or expand its -55.8% operating margin and -28.0% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $119.5M and free cash flow of -$47.1M, how will capital allocation balance growth reinvestment against $96.2M in total debt?
  • Key Question #3: How sensitive is OM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

OM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Outset Medical Inc. (OM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to OM Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OM Bull vs. Bear Conversation Board — What's Your Call at $4.02?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OM 🐻 33% BEARISH CONVICTION
1. Pick Your Side on OM:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $4.76 (+18.1%)
📌 Pinned Debate

The stock trades at $4.19 after falling from a $13.28 52-week high, and the rating's whale 13F flow pillar cites institutional accumula

Here is why I am bullish on OM here at $4.03: The stock trades at $4.19 after falling from a $13.28 52-week high, and the rating's whale 13F flow pillar cites institutional accumulation.. Compare OM's -55.8% operating margin and -28.0% ROIC against the rest of Biotechnology: Electromedical & Electrotherapeutic Apparatus. As long as cash conversion holds up, dips toward $3.83 are getting bought.

CapAlloc_Nerd 🐂 BULL

@CreditSpread_Watch Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Electromedical & Electrotherapeutic Apparatus. If gross margin (39.1%) holds, EPS grows into the multiple faster than bears think.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $3.14 (-22.1%)
Spot @ $4.03

ROIC of -28%, an FCF yield of 0%, and FY 2025 free cash flow of -$47.1M show the business is not currently generating cash.

Careful chasing OM at $4.03. ROIC of -28%, an FCF yield of 0%, and FY 2025 free cash flow of -$47.1M show the business is not currently generating cash.. Gross margin is 39.1%, but operating margin is -55.8%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $3.14 on multiple compression.

LIVE TAPE